Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial

Youyi Fong, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Lauren Dang, Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Bo Zhang, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Jonathan Fintzi, Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Shiyu Chen, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Jing Wang, Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Nadine G. Rouphael, Hope Clinic, Emory University, Decatur, Georgia, USA.
Angela R. Branche, Vaccine and Treatment Evaluation Unit, University of Rochester, Rochester, New York, USA.
David J. Diemert, George Washington Vaccine Research Unit, George Washington University, Washington, District of Columbia, USA.
Ann R. Falsey, Vaccine and Treatment Evaluation Unit, University of Rochester, Rochester, New York, USA.
Cecilia Losada, Hope Clinic, Emory University, Decatur, Georgia, USA.
Lindsey R. Baden, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Sharon E. Frey, Center for Vaccine Development, Saint Louis University, Missouri, USA.
Jennifer A. Whitaker, Department of Molecular Virology and Microbiology and Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Susan J. Little, Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla, California, USA.
Satoshi Kamidani, Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Georgia, USA.
Emmanuel B. Walter, Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Richard M. Novak, Project WISH, University of Illinois at Chicago, Chicago, Illinois, USA.
Richard Rupp, Department of Pediatrics, University of Texas Medical Branch, Galveston, Texas, USA.
Lisa A. Jackson, Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.
Chenchen Yu, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Craig A. Magaret, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Cindy Molitor, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Bhavesh Borate, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Tara M. Babu, Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.
Angelica C. Kottkamp, Vaccine and Treatment Evaluation Unit, Manhattan Research Clinic, New York University Grossman School of Medicine, New York, New York, USA.
Anne F. Luetkemeyer, Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, California, USA.
Lilly C. Immergluck, Clinical Research Center, Department of Microbiology, Biochemistry, and Immunology, Morehouse School of Medicine, Atlanta, Georgia, USA.
Rachel M. Presti, Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA.
Martín Bäcker, Vaccine and Treatment Evaluation Unit, Long Island Research Clinic, New York University, Long Island School of Medicine, Mineola, New York, USA.
Patricia L. Winokur, Department of Medicine, University of Iowa College of Medicine, Iowa City, Iowa, USA.
Siham M. Mahgoub, Howard University College of Medicine, Howard University Hospital, Washington, District of Columbia, USA.

Document Type

Journal Article

Publication Date

9-26-2024

Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

DOI

10.1093/cid/ciae465

Keywords

COVID-19 booster; Omicron; correlate of risk; exposure-proximal titer; variant vaccine booster

Abstract

For COVAIL recipients of a COVID-19 Sanofi booster vaccine, neutralizing antibody titers were assessed as a correlate of risk (CoR) of COVID-19. Peak and exposure-proximal titers were inverse CoRs with covariate-adjusted hazard ratios (95% confidence intervals) 0.30 (0.11, 0.78) and 0.25 (0.07, 0.85) per 10-fold increase in weighted average titer.

Department

Medicine

Link to Full Text

Share

COinS